Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...

It wasn’t like any other birthday for Rosella Nix, a resident at the Wesley House Assisted Living Center in Gilmer.

In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients treated with nab ...

Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

2 Rosella Court, Bethanga is a 3 bedroom house. What are the key property features of 2 Rosella Court, Bethanga? To enquire about specific property features for 2 Rosella Court, Bethanga ...

Results will support a New Drug Application (NDA) in the United States and a Marketing Authorization Application (MAA) in Europe Relacorilant plus nab-paclitaxel has the potential to become a new ...